Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
Renee P Tannenbaum bought 10,000 shares of CRDF on 12 December at $3.42 per share, worth a total of $34K. They now own 20,000 CRDF shares, or a 100% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
